Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial
Purpose In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT) results in long-term tumor control of approximately 80%. We aimed to improv...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 23, 2012
|
| In: |
Journal of clinical oncology
Year: 2012, Jahrgang: 30, Heft: 9, Pages: 907-913 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2011.38.5807 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1200/JCO.2011.38.5807 Verlag, Volltext: http://ascopubs.org/doi/10.1200/JCO.2011.38.5807 
|
| Verfasserangaben: | Bastian von Tresckow, Annette Plütschow, Michael Fuchs, Beate Klimm, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max S. Topp, Julia Meissner, Josée M. Zijlstra, Martin Soekler, Harald Stein, Hans T. Eich, Rolf P. Mueller, Volker Diehl, Peter Borchmann, and Andreas Engert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577807766 | ||
| 003 | DE-627 | ||
| 005 | 20220814195229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180720s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2011.38.5807 |2 doi | |
| 035 | |a (DE-627)1577807766 | ||
| 035 | |a (DE-576)507807766 | ||
| 035 | |a (DE-599)BSZ507807766 | ||
| 035 | |a (OCoLC)1341014252 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Tresckow, Bastian von |d 1977- |e VerfasserIn |0 (DE-588)130370932 |0 (DE-627)500426538 |0 (DE-576)298155087 |4 aut | |
| 245 | 1 | 0 | |a Dose-intensification in early unfavorable Hodgkin's lymphoma |b final analysis of the German Hodgkin study group HD14 trial |c Bastian von Tresckow, Annette Plütschow, Michael Fuchs, Beate Klimm, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max S. Topp, Julia Meissner, Josée M. Zijlstra, Martin Soekler, Harald Stein, Hans T. Eich, Rolf P. Mueller, Volker Diehl, Peter Borchmann, and Andreas Engert |
| 264 | 1 | |c January 23, 2012 | |
| 300 | |b Diagramme | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.07.2018 | ||
| 520 | |a Purpose In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT) results in long-term tumor control of approximately 80%. We aimed to improve these results using more intensive chemotherapy. Patients and Methods Patients with newly diagnosed early unfavorable HL were randomly assigned to either four cycles of ABVD or an intensified treatment consisting of two cycles of escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) followed by two cycles of ABVD (2 + 2). Chemotherapy was followed by 30 Gy IFRT in both arms. The primary end point was freedom from treatment failure (FFTF); secondary end points included progression-free survival (PFS) and treatment-related toxicity. Results With a total of 1,528 qualified patients included, the 2 + 2 regimen demonstrated superior FFTF compared with four cycles of ABVD (P < .001; hazard ratio, 0.44; 95% CI, 0.30 to 0.66), with a difference of 7.2% at 5 years (95% CI, 3.8 to 10.5). The difference in 5-year PFS was 6.2% (95% CI, 3.0% to 9.5%). There was more acute toxicity associated with 2 + 2 than with ABVD, but there were no overall differences in treatment-related mortality or secondary malignancies. Conclusion Intensified chemotherapy with two cycles of BEACOPP escalated followed by two cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL. | ||
| 700 | 1 | |a Meißner, Julia |e VerfasserIn |0 (DE-588)1236765966 |0 (DE-627)176254850X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 30(2012), 9, Seite 907-913 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Dose-intensification in early unfavorable Hodgkin's lymphoma final analysis of the German Hodgkin study group HD14 trial |
| 773 | 1 | 8 | |g volume:30 |g year:2012 |g number:9 |g pages:907-913 |g extent:7 |a Dose-intensification in early unfavorable Hodgkin's lymphoma final analysis of the German Hodgkin study group HD14 trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2011.38.5807 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/10.1200/JCO.2011.38.5807 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180720 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1236765966 |a Meißner, Julia |m 1236765966:Meißner, Julia |d 910000 |d 910100 |e 910000PM1236765966 |e 910100PM1236765966 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 999 | |a KXP-PPN1577807766 |e 3019150914 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"relHost":[{"recId":"313116962","id":{"zdb":["2005181-5"],"eki":["313116962"],"issn":["1527-7755"]},"pubHistory":["1.1983 -"],"part":{"extent":"7","text":"30(2012), 9, Seite 907-913","volume":"30","pages":"907-913","year":"2012","issue":"9"},"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"title":[{"title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology"}],"origin":[{"dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins"}],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Society of Clinical Oncology","role":"isb"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Dose-intensification in early unfavorable Hodgkin's lymphoma final analysis of the German Hodgkin study group HD14 trialJournal of clinical oncology","language":["eng"]}],"physDesc":[{"extent":"7 S.","noteIll":"Diagramme"}],"note":["Gesehen am 20.07.2018"],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"January 23, 2012"}],"title":[{"subtitle":"final analysis of the German Hodgkin study group HD14 trial","title":"Dose-intensification in early unfavorable Hodgkin's lymphoma","title_sort":"Dose-intensification in early unfavorable Hodgkin's lymphoma"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Tresckow, Bastian von","given":"Bastian von","family":"Tresckow"},{"role":"aut","family":"Meißner","display":"Meißner, Julia","roleDisplay":"VerfasserIn","given":"Julia"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Bastian von Tresckow, Annette Plütschow, Michael Fuchs, Beate Klimm, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max S. Topp, Julia Meissner, Josée M. Zijlstra, Martin Soekler, Harald Stein, Hans T. Eich, Rolf P. Mueller, Volker Diehl, Peter Borchmann, and Andreas Engert"]},"recId":"1577807766","id":{"doi":["10.1200/JCO.2011.38.5807"],"eki":["1577807766"]}} | ||
| SRT | |a TRESCKOWBADOSEINTENS2320 | ||